These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6112126)

  • 41. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes.
    Seeman P
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):3S-9S. PubMed ID: 2906067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage.
    Lipska BK; Weinberger DR
    Neuropsychopharmacology; 1994 May; 10(3):199-205. PubMed ID: 7916917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dyskinesia: animal experimental correlates.
    Moore KE
    Acta Psychiatr Scand Suppl; 1981; 291():88-102. PubMed ID: 6113737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 2007 Apr; 29(3):211-6. PubMed ID: 17520104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dyskinesia induced by long-term treatment with antipsychotic drugs: involvement of pre- and postsynaptic dopaminergic mechanisms.
    Engel J; Liljequist S; Goldstein M
    Adv Biochem Psychopharmacol; 1980; 23():387-95. PubMed ID: 6104913
    [No Abstract]   [Full Text] [Related]  

  • 47. Effects of 6-hydroxydopamine-induced lesions of A10 dopaminergic neurons and neuroleptic or bromocriptine treatment on ethanol withdrawal syndrome in rats.
    Trzaskowska E; Puciłowski O; Kostowski W; Bidziński A
    Pol J Pharmacol Pharm; 1983; 35(5):339-49. PubMed ID: 6141554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tardive dyskinesia. Pathophysiological mechanisms and clinical trials.
    Gerlach J
    Encephale; 1988 Sep; 14 Spec No():227-32. PubMed ID: 2905651
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The therapeutic latency of neuroleptic drugs and nonspecific postjunctional supersensitivity.
    Freed WJ
    Schizophr Bull; 1988; 14(2):269-77. PubMed ID: 2904695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
    Lynch MR
    Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH; Diamond BI
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel oral drug administration in an animal model of neuroleptic therapy.
    Schleimer SB; Johnston GA; Henderson JM
    J Neurosci Methods; 2005 Aug; 146(2):159-64. PubMed ID: 16054505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Postnatal iron-induced motor behaviour alterations following chronic neuroleptic administration in mice.
    Fredriksson A; Eriksson P; Archer T
    J Neural Transm (Vienna); 2006 Feb; 113(2):137-50. PubMed ID: 16082515
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs.
    Luchins DJ; Freed WJ; Wyatt RJ
    Am J Psychiatry; 1980 Nov; 137(11):1395-8. PubMed ID: 6108078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal.
    De Souza IE; Dawson NM; Clifford JJ; Waddington JL; Meredith GE
    Psychopharmacology (Berl); 2003 Aug; 169(1):28-34. PubMed ID: 12830366
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Respiratory dyskinesia and dysarthria from prolonged neuroleptic use: tardive dyskinesia?
    Faheem AD; Brightwell DR; Burton GC; Struss A
    Am J Psychiatry; 1982 Apr; 139(4):517-8. PubMed ID: 6121492
    [No Abstract]   [Full Text] [Related]  

  • 58. Oral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in rats.
    Shireen E; Naeem S; Inam QU; Haleem DJ
    Pak J Pharm Sci; 2013 Mar; 26(2):271-6. PubMed ID: 23455196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment.
    Vonvoigtlander PF; Losey EG; Triezenberg HJ
    J Pharmacol Exp Ther; 1975 Apr; 193(1):88-94. PubMed ID: 166158
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The common marmoset (Callithrix jacchus) as a model for neuroleptic-induced acute dystonia.
    Fukuoka T; Nakano M; Kohda A; Okuno Y; Matsuo M
    Pharmacol Biochem Behav; 1997 Dec; 58(4):947-53. PubMed ID: 9408199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.